![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DD Stiff and MA Zemaitis
Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, PA 15261.
The metabolism of zonisamide [3-(sulfamoylmethyl)-1,2-benzisoxazole], a new anticonvulsant, has been studied. In rats dosed with [14C]zonisamide (100 mg/kg, ip) 86.5% of the radioactive dose was excreted in the urine over 72 hr. The remainder of the radioactive dose (13.5%) was excreted in the feces over the same time period. Unchanged drug and eight metabolites were isolated from the urine, and the structures of five metabolites were assigned by physicochemical methods. metabolism of zonisamide primarily involves reductive and conjugative mechanisms, with oxidation of this compound being of minor metabolic significance. The percentage of urinary radioactivity accounted for by unmetabolized zonisamide and metabolites is as follows: unmetabolized zonisamide (metabolite 9), 32.8%; metabolite 8 [N-acetyl-3-(sulfamoylmethyl)-1,2-benzisoxazole], 7.7%; unidentified metabolite 7, 2.4%; metabolite 6 (zonisamide glucuronide), 7.6%; metabolite 5 [3-(carboxy)-1,2-benzisoxazole], 5.4%; unidentified metabolite 4, 13.1%; metabolite 3 [2-(sulfamoylacetyl)-phenol glucuronide], 12.6%; unidentified metabolite 2, 3.8%; and metabolite 1 (2-[1-(amino)sulfamoylethyl]phenol sulfate), 2.3%. A total of 87.7% of the 0-24 hr urinary radioactivity was accounted for by unchanged zonisamide and metabolites.
This article has been cited by other articles:
|
|
 |
|
  A. S. Kalgutkar, H. T. Nguyen, A. D. N. Vaz, A. Doan, D. K. Dalvie, D. G. McLeod, and J. C. Murray IN VITRO METABOLISM STUDIES ON THE ISOXAZOLE RING SCISSION IN THE ANTI-INFLAMMATORY AGENT LEFLUNOMIDE TO ITS ACTIVE {alpha}-CYANOENOL METABOLITE A771726: MECHANISTIC SIMILARITIES WITH THE CYTOCHROME P450-CATALYZED DEHYDRATION OF ALDOXIMES Drug Metab. Dispos., October 1, 2003; 31(10): 1240 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Tschirret-Guth and H. B. Wood SUBSTITUENT EFFECT ON THE REDUCTIVE N-DEARYLATION OF 3-(INDOL-1-YL)-1,2-BENZISOXAZOLES BY RAT LIVER MICROSOMES Drug Metab. Dispos., August 1, 2003; 31(8): 999 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. E. Leppik Three New Drugs for Epilepsy: Levetiracetam, Oxcarbazepine, and Zonisamide J Child Neurol, January 1, 2002; 17(1_suppl): S53 - S57. [Abstract] [PDF]
|
|
|
|
|
|
C. Prakash, A. Kamel, J. Gummerus, and K. Wilner Metabolism and Excretion of a New Antipsychotic Drug, Ziprasidone, in Humans Drug Metab. Dispos., July 1, 1997; 25(7): 863 - 0. [Abstract] [Full Text]
|
|
|
|
|
|
C. Prakash, A. Kamel, and D. Cui Characterization of the Novel Benzisothiazole Ring-Cleaved Products of the Antipsychotic Drug Ziprasidone Drug Metab. Dispos., July 1, 1997; 25(7): 897 - 901. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
